According to the Zhitong Finance APP, aesthetic medicine concept stocks collectively fell. As of the time of publication, ec healthcare (02138) fell by 5.45%, reporting HKD 1.04; shanghai haohai biological technology (06826) fell by 4.56%, reporting HKD 30.35; sisram med (01696) fell by 3.69%, reporting HKD 3.13.

CaiXin Securities released a research report stating that the demand for medical aesthetics may be temporarily under pressure due to continuous weak consumer recovery, downgraded consumption, and terminal price wars. However, the long-term growth logic of the industry has not changed. Debon Securities pointed out that under the high base effect in Q2, the same increase is slightly under pressure, and high-end optional consumption is affected by the macro environment. Market competition intensifies with the launch of multiple new products such as regeneration and collagen. Despite being the off-season for Q3 due to hot weather and travel restrictions, the growth rate is expected to improve month-on-month due to the low base effect. The marginal improvement effect in the peak season of medical aesthetics in 24Q4 may be more obvious.

In addition, Morgan Stanley's report pointed out that under the continuing unfavorable factors of anti-corruption, the market believes that the performance of medical technology companies in the second quarter is weak. Investors are paying close attention to the timetable and scale of the upcoming fiscal stimulus plan to set expectations for medical technology stocks in the second half of this year and next year. At the same time, unfavorable macro and policy factors may continue to drag on the growth of consumption and medical aesthetics companies.